ANTIHYPERTENSIVE AND ORGANOPROTECTIVE EFFICACY OF A FIXED-DOSE COMBINATION OF TELMISARTAN AND AMLODIPINE IN PATIENTS WITH ARTERIAL HYPERTENSION
Abstract
Arterial hypertension (AH) remains a leading modifiable risk factor for cardiovascular disease. Left ventricular (LV) hypertrophy and increased carotid intima-media thickness (IMT) are markers of target-organ damage, and their regression during antihypertensive therapy is associated with a reduced risk of stroke and cardiovascular complications. Fixed-dose combinations provide more pronounced blood pressure (BP) reduction through complementary mechanisms of action and improve treatment adherence. To evaluate the antihypertensive, cardioprotective, and vasoprotective efficacy of six-month therapy with a fixed-dose telmisartan/amlodipine combination in patients with grade I–II AH. The prospective study included 49 patients with primary grade I–II AH followed on an outpatient basis (mean age 52.3±13.7 years; 61.2% women; AH duration 5.1±4.1 years). The diagnosis was established in accordance with the 2023 European Society of Hypertension (ESH) guidelines. All patients received a fixed-dose telmisartan/amlodipine combination at a mean daily dose of 60±20/5 mg, titrated every 2 weeks until the target BP was achieved. At baseline and after 6 months, office BP measurement, 24-hour ambulatory BP monitoring (ABPM), echocardiography with calculation of left ventricular mass (LVM) and its index (LVMI), and carotid duplex ultrasonography with measurement of intima-media thickness were performed. Statistical analysis was carried out using the paired Student's t-test and the Wilcoxon signed-rank test; differences were considered statistically significant at p<0.05.
Publication Details
This article is licensed under a Creative Commons Attribution 4.0 International License.